Moderna, Inc. financial data

Symbol
MRNA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
325 Binney Street, Cambridge, MA
Fiscal year end
December 31
Former names
Moderna Therapeutics, Inc. (to 8/24/2016)
Latest financial report
10-Q - Q1 2025 - May 1, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 408 % +27.5%
Quick Ratio 12.6 % -4.25%
Debt-to-equity 30.8 % -9.56%
Return On Equity -30.1 % +28%
Return On Assets -23 % +26.2%
Operating Margin 4.82 % -92.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 387M shares +0.91%
Common Stock, Shares, Outstanding 387M shares +1.04%
Entity Public Float 42.1B USD +4.73%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 386M shares +1.05%
Weighted Average Number of Shares Outstanding, Diluted 386M shares +1.05%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 10.7B USD -53.7%
Revenue from Contract with Customer, Excluding Assessed Tax 3.18B USD -38.3%
Research and Development Expense 4.34B USD -9.23%
General and Administrative Expense 1.11B USD -26.7%
Costs and Expenses 6.91B USD -32.9%
Operating Income (Loss) -3.73B USD +27.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -3.41B USD +29.1%
Income Tax Expense (Benefit) -49M USD -104%
Net Income (Loss) Attributable to Parent -3.36B USD +43.8%
Earnings Per Share, Basic -8.73 USD/shares +44%
Earnings Per Share, Diluted -8.73 USD/shares +44%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.62B USD -20.9%
Accounts Receivable, after Allowance for Credit Loss, Current 78M USD -43.1%
Inventory, Net 128M USD -56.6%
Other Assets, Current 69M USD +1.47%
Assets, Current 6.77B USD -29.5%
Deferred Income Tax Assets, Net 81M USD 0%
Operating Lease, Right-of-Use Asset 752M USD +7.89%
Goodwill 52M USD 0%
Other Assets, Noncurrent 556M USD -14.5%
Assets 12.7B USD -24.1%
Accounts Payable, Current 226M USD +23.5%
Employee-related Liabilities, Current 120M USD +26.3%
Accrued Liabilities, Current 1B USD -28.3%
Contract with Customer, Liability, Current 125M USD -77.6%
Liabilities, Current 1.6B USD -32.6%
Contract with Customer, Liability, Noncurrent 58M USD 0%
Deferred Income Tax Liabilities, Net 234M USD
Operating Lease, Liability, Noncurrent 667M USD +4.71%
Other Liabilities, Noncurrent 274M USD +4.58%
Liabilities 2.64B USD -32.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 10M USD
Retained Earnings (Accumulated Deficit) 9.07B USD -27%
Stockholders' Equity Attributable to Parent 10.1B USD -21.5%
Liabilities and Equity 12.7B USD -24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.04B USD -4.85%
Net Cash Provided by (Used in) Financing Activities 4M USD -71.4%
Net Cash Provided by (Used in) Investing Activities 730M USD +519%
Common Stock, Shares Authorized 1.6B shares 0%
Common Stock, Shares, Issued 387M shares +1.04%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -303M USD +64.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.63B USD -21.5%
Deferred Tax Assets, Valuation Allowance 3.08B USD +38.7%
Deferred Tax Assets, Gross 3.36B USD +25.5%
Operating Lease, Liability 682M USD +3.02%
Payments to Acquire Property, Plant, and Equipment 117M USD -40.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -3.25B USD +44.1%
Lessee, Operating Lease, Liability, to be Paid 1.12B USD 0%
Operating Lease, Liability, Current 15M USD -40%
Lessee, Operating Lease, Liability, to be Paid, Year Two 77M USD +14.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 72M USD +7.46%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 433M USD -4.42%
Lessee, Operating Lease, Liability, to be Paid, Year Three 80M USD +14.3%
Deferred Tax Assets, Operating Loss Carryforwards 424M USD +371%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 162M shares 0%
Unrecognized Tax Benefits 240M USD +3.9%
Lessee, Operating Lease, Liability, to be Paid, Year Four 82M USD +13.9%
Additional Paid in Capital 982M USD +102%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 188M USD -67.2%
Deferred Tax Assets, Net of Valuation Allowance 277M USD -39%
Share-based Payment Arrangement, Expense 443M USD +33.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%